Rivaroxaban
Abbrev Code: | RVXBAN | ||
Order Code: | LAB8193 | Order Name: | Rivaroxaban |
Synonyms: | Xarelto | ||
Methodology: | Chromogenic | ||
CPT Codes: | 80299 x1, 80299 x1 | ||
Turnaround Time: | Testing is performed as needed; results are reported within 8 hours if received into the testing laboratory by 12 p.m. Testing performed 6 days per week. With pre-notification, STATs are done within 1 hour after receipt in the testing laboratory. | ||
Special Instructions: | See link to Specimen Collection and Processing for Coagulation Specimens
Testing should not be performed on patients receiving the reversal agent Andexxa. This anti-Xa assay is not suitable for measuring reversal activity of Andexxa® due to high sample dilutions, which cause dissociation of the inhibitor from Andexxa. Peak levels are drawn 2-4 hours post dosage. |
||
Associated Links: | Specimen Collection and Processing for Coagulation Specimens |
Collection Instructions
Specimen: | Blood |
Optimal Volume: | 2.7 mL (in 3 mL tube) - filled to fill line on the tube. |
Minimum\Peds Volume: | 1.8 mL (in 2 mL tube) - filled to fill line on tube |
Container: | Blue Na Citrate, 3.2% - fill to fill line on tube |
Collection Instructions: | Peak levels are drawn 2-4 hours post dosage.
See link to Specimen Collection and Processing for Coagulation Specimens. |
Causes for Rejection: | Underfilled tubes, overfilled tubes, clotted specimens, not received or processed and frozen within 4 hours of collection or, specimen thawed during transit. |
Processing and Shipping
Specimen Processing: |
|
Shipping Instructions: |
|
Stability: | 4 hours at room temperature |
Test Performed at or Referral Lab | UM Special Coag (K) (UMMC East Bank) |
Interpretive
Therapeutic Range: | Therapeutic ranges have not been established for rivaroxaban. Target "on therapy" ranges are based on levels measured in subjects in clinical trials published in the literature. The on therapy range peak level measured 2-4 hours after taking the oral dose is approximately 184-343 nanogram/mL for 20 mg daily for stroke prevention in non-valvular atrial fibrilation and 189-419 nanogram/mL for 20 mg daily for acute treatment of deep venous thrombosis. {European Medicines Agency. Committee for Medicinal Products for Human Use. Assessment Report:Xarelto (rivaroxaban) EMA/42547/2012. September 22, 2011 Accessed December 6, 2019. Mueck et al. Clin Pharmacokinet 2011, 50:675-686; Mueck et al. Clin Pharmacokinet 2014;53:1-16] |
Use: | Rivaroxaban (Xarelto®) assay is an anti-Xa calibrated for rivaroxaban only. |
Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
[email protected] for TestID: 6826"